Rather than conducting a new meta-analysis, the authors synthesize findings from major randomized clinical trials, highlighting outcomes related to glycated hemoglobin (HbA1c), body weight reduction, major adverse cardiovascular events (MACE), and kidney function decline as reported in large cardiovascular outcomes trials (CVOTs), obesity randomized controlled trials, and early-phase clinical development studies
The Bottom Line The AbundRX GLP-1 program is a telehealth entry point into compounded semaglutide or tirzepatide care, described by the brand as a three-step process involving intake, provider review, and treatment access if prescribed
Review your plans prescription drug formulary Coverage varies widely between insurers
Decongestants like pseudoephedrine may slightly increase heart rate or blood pressure in some individuals, but this effect is unrelated to semaglutide itself
Take the next step with Empower Download our product guide and learn more about how Empower can support your business
[PMID: 29799100] PubMed record related to this compound for laboratory literature review